Single-dose ticagrelor does not prolong the QT interval in healthy subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 10, 2010, Pages 643-651

  Butler, K ^a   Wei, C ^a   Teng, R ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Antiplatelet therapy; AZD6140; QT QTc interval; Ticagrelor

Indexed keywords

AR C124910XX; MOXIFLOXACIN; PLACEBO; PURINERGIC RECEPTOR BLOCKING AGENT; TICAGRELOR; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ELECTROCARDIOGRAM; EPISTAXIS; HEART RATE; HEART REPOLARIZATION; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PROTHROMBIN TIME; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 77957660324     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48643     Document Type: Article

References (23)

1. Algra A, Tijssen JGP, Roelandt JRTC, Pool J, Lubsen J. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation. 1991; 83: 1888-1894.
2. Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, Storey RF, for the DISPERSE- 2 investigators. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007; 50: 1844-1851. (Pubitemid 350007959)
3. Crumb W, Cavero II. QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. Pharm Sci Technolo Today. 1999; 2: 270-280. (Pubitemid 29331975)
4. Darpo B, Nebout T, Sager PT. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. J Clin Pharmacol. 2006; 46: 498-507.
5. Démolis JL,KubitzaD, Tennezé L, Funck-Brentano C. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther. 2000; 68: 658-666. (Pubitemid 32059992)
6. 12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006; 27: 1038-1047.
7. 12 receptor antagonist. Cardiovasc Ther. 2009; 27: 259-274.
8. ICH E14 guidance. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. May 12, 2005. Available from URL: http://www.ich.org/LOB/media/MEDIA1476.pdf; accessed February 9; 2010.
9. 12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2009; 157: 599-605.
10. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU,Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002; 287: 2215-2220.
11. MacGowan AP. Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. Expert Opin Investig Drugs. 1999; 8: 181-199.
12. Noel GJ, Natarajan J, Chien, S, Hunt TL, Goodman DB, Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther. 2003; 73: 292-303. (Pubitemid 36403589)
13. Ponte ML, Keller GA, Di Girolamo G. Mechanisms of drug induced QT interval prolongation. Curr Drug Saf. 2010; 5: 44-53.
14. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004; 350: 1013-1022.
15. Schwartz PJ, Periti M, Malliani A. The long Q-T syndrome. Am Heart J. 1975; 89: 378-390.
16. 12 receptor antagonist for the prevention of thrombosis. Bioorg Med Chem Lett. 2007; 17: 6013-6018.
17. 12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. JAmColl Cardiol. 2007; 50: 1852-1856.
18. Straus SM, Kors JA, De Bruin ML, van der Hooft CS, Hofman A, Heeringa J, Deckers JW, Kingma JH, Sturkenboom MC, Stricker BH, Witteman JC. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol. 2006; 47: 362-367. (Pubitemid 43063255)
19. Tantry US, Bliden KP, Gurbel PA. AZD6140. Expert Opin Investig Drugs. 2007; 16: 225-229.
20. 12 receptor antagonist, has linear pharmacokinetics and provides near complete inhibition of platelet aggregation, with reversibility of effect, in healthy subjects. Can J Clin Pharmacol. 2008; 15: e426.
21. 12 receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 2010; 66: 487-496.
22. 12 antagonists. Semin Thromb Hemost. 2005; 31: 195-204.
23. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361: 1045-1057.